Health economic consequences of irbesartan treatment of type 2 diabetes patients with nephropathy and hypertension in Germany;Gesundheitsökonomische Aspekte der Anwendung von Irbesartan bei Patienten mit Typ-2-Diabetes, Nephropathie und Hypertonie in Deutschland

Deutsche Medizinische Wochenschrift

Volumn 129, Issue 1-2, 2004, Pages 13-18

  Palmer, A J ^a   Annemans, L ^b,c   Roze, S ^a   Lamotte, M ^b   Rodby, R A ^d   Ritz, E ^e  

^a IQVIA   (United States)

^b Health Economics and Disease Management   (Belgium)

^c GHENT UNIVERSITY   (Belgium)

^d Department of Internal Medicine   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; IRBESARTAN;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG COST; HEALTH ECONOMICS; HUMAN; HYPERTENSION; KIDNEY DISEASE; LONG TERM CARE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; TREATMENT OUTCOME;

EID: 0347126575     PISSN: 00120472     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-812656     Document Type: Article

References (34)

1. BKK (Hrsg.). Sozialgesetze Gesamtausgabe 2002 Sozialgesetzbuch V vom 20. Dezember 1988 (BGBI. I S. 2477) Zuletzt geändert durch Artikel 1 des Gesetzes vom 19. Dezember 2001(BGBI. I S. 3773) MBO Verlag GmbH, Münster, 2002, 2002
2. Boucek P, Saudek F, Pokorna E et al.. Kidney transplantation in type 2 diabetic patients: a comparison with matched non-diabetic subjects. Nephrol Dial Transplan 2002; 17: 1678-1683
3. Brenner BM, Cooper ME, de Zeeuw D et al.. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869
4. Clarke P, Gray A, Adler A et al.. Cost-effectiveness analysis of intensive blood-glucose control with metformin in overweight patients with type II diabetes (UKPDS No. 51). Diabetologia 2001; 44: 298-304
5. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324: 71-86
6. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 2002; 287: 2542-2551
7. Detsky AS, Naglie G, Krahn MD, Naimark D, Redelmeier DA. Primer on medical decision analysis: Part 1 - Getting started. Med Decis Making 1997; 17: 123-125
8. Detsky AS, Naglie G, Krahn MD, Redelmeier DA, Naimark D. Primer on medical decision analysis: Part 2 - Building a tree. Med Decis Making 1997; 17: 125-135
9. Deutsche Arbeitsgemeinschaft für klinische Nephrologie e.V. und Deutsche Dialysegesellschaft Niedergelassener Ärzte e.V.(Hrsg.). Dialysestandard 2000. Mitt Klin Nephrologie 2001: 91-134
10. Gerth WC, Remuzzi G, Viberti G et al.. Losartan reduces the burden and cost of ES RD: Public health implications from the RENAAL study for the European Union. Kidney Int 2002; 62 (Suppl 82): 68-72
11. Gozzoli V, Palmer AJ, Brandt A et al.. Increased clinical and economic advantages using PROSIT (proteinuria screening and intervention) in type 2 diabetic patients. Dtsch Med Wochenschr 2000; 125: 1154-1159
12. Greiner W. Ökonomische Evaluation von Gesundheitsleistungen. Fragestellungen, Methoden und Grenzen dargestellt am Beispiel der Transplantationsmedizin. Nomos, Baden-Baden, 1999
13. Halimi S, Zmirou D, Benhamou PY et al.. Huge progression of diabetes prevalence and incidence among dialysed patients in mainland France and overseas French territories: A second national survey six years apart (UREMIDIAB 2 study). Diabetes Metab 1999; 25: 507-512
14. Hannover Consensus Group. German recommendations for health care economic evaluation studies. Revised version of the Hannover consensus. Med Klin 2000; 95: 52-55
15. Hannoverian Consensus Group. German recommendations for health economic evaluation. Revised edition of the Hannoverian consensus. Dtsch Med Wochenschr 1999; 124: 1503-1506
16. Herman WH, Shahinfar S, Carides GW et al.. Losartan Reduces the Costs Associated With Diabetic End-Stage Renal Disease: The RENAAL study economic evaluation. Diabetes Care 2003; 26: 683-687
17. Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med 2001; 345: 910-912
18. Jonsson B. The economic impact of diabetes. Diabetes Care 1998; 21 (Suppl 3): C7-10
19. Lewis EJ, Hunsicker LG, Clarke WR et al.. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851-860
20. Liebl A, Neiss A, Spannheimer A et al.. Costs of type 2 diabetes in Germany: Results of the CODE-2 study. Dtsch Med Wochenschr 2001; 126: 585-589
21. Naimark D, Krahn MD, Naglie G et al.. Primer on medical decision analysis: Part 5 - Working with Markov processes. Med Decis Making 1997; 17: 152-159
22. Nebel M. Behandlungskosten der Nierenersatztherapie in Deutschland 1999. Nieren- und Hochdruckkrankheiten 2002; 31: 85-92
23. Palmer AJ, Annemans L, Roze S et al.. An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy; cost-effectivenesss of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian, and French settings. Nephrol Dial Transplant 2003; 18: 2059-2066
24. QuaSi-Niere GmbH. Annual Report 2000. www.quasi-niere.de, 2002
25. Ritz E, Bergis K, Strojek K, Keller C. Nephropathy and hypertension in type II diabetes. Med Klin 1997; 92: 421-425
26. Ritz E, Rychlik I, Locatelli F, Halimi S. End-stage renal failure in type 2 diabetes: A medical catastrophe of worldwide dimensions. Am J Kidney Dis 1999; 34: 795-808
27. Rodby RA, Chiou CF, Borenstein J et al.. The cost-effectivness of irbesartan in the treatment of hypertensive patients with type 2 diabetic nephropathy. Clin Ther 2003; 25: 2103-2119
28. Rote Liste Service GmbH. Rote Liste - Arzneimittelverzeichnis für Deutschland. 2001
29. Schwabe U. Arzneiverordnungsreport 2001. Springer-Verlag Heidelberg, 2002
30. Statistisches Bundesamt Deutschland. Preisindizes für die Lebenshaltung. www.statistisches-bundesamt.de, 2002
31. Stein G, Funfstuck R, Sperschneider H, Ritz E. Nephrology update kidney protection with antihypertensive drugs: I Med Klin 2002; 97: 541-546
32. U.S. Renal Data System. USRDS 2001 Annual Data Report Atlas of End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2001
33. UKPDS Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853
34. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-1258